Johnson & Johnson (JNJ) closed at $145.97 in the latest trading session, marking a -1.24% move from the prior day.
J&J (JNJ) seeks expanded use of its HIV-1 therapy, Prezcobix, for younger kids in the United States and Europe.
NEW BRUNSWICK, N.J., June 04, 2024--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, July 17th to review second-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Jessica Moore, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson’s execut